A., Feldpausch, M
For more information, please read on or give us a call
6.1.2 WILLOW study (phase II clinical trial) 6.1.2.1 Study design and population The WILLOW study represented a pivotal Phase II clinical trial of brensocatib in bronchiectasis patients ( The study recruited 416 patients total, with 256 patients meeting inclusion criteria completing randomization, allocated to placebo group (87 patients), 10 mg brensocatib group (82 patients), and 25 mg brensocatib group (87 patients)
Before transitioning into health, Victoria earned a degree in Economics and an MBA, working with corporations including Canon and Vodafone
In other words, the cellular compartments have different GSH/GSSG ratios, and the life cell cycle is also associated with different thiol redox potentials, which can alter the cellular functions
Nakamura Y, Sugihara K, Sone T, Isobe M, Ohta S, Kitamura S